vs
Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and ROGERS CORP (ROG). Click either name above to swap in a different company.
HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $200.5M, roughly 1.4× ROGERS CORP). ROGERS CORP runs the higher net margin — 2.2% vs 0.7%, a 1.5% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs -16.5%). HUTCHMED (China) Ltd produced more free cash flow last quarter ($3.4M vs $1.1M).
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
HCM vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.8M | $200.5M |
| Net Profit | $2.0M | $4.5M |
| Gross Margin | 37.7% | 32.2% |
| Operating Margin | -13.2% | — |
| Net Margin | 0.7% | 2.2% |
| Revenue YoY | -16.5% | 5.2% |
| Net Profit YoY | -83.6% | 421.4% |
| EPS (diluted) | $0.00 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $270.8M | $201.5M | ||
| Q3 25 | — | $216.0M | ||
| Q2 25 | $277.7M | $202.8M | ||
| Q1 25 | $324.5M | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | — | $210.3M | ||
| Q2 24 | $305.7M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $2.0M | $4.6M | ||
| Q3 25 | — | $8.6M | ||
| Q2 25 | $455.0M | $-73.6M | ||
| Q1 25 | $11.9M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | $25.8M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 37.7% | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | 0.1% | 31.6% | ||
| Q1 25 | 48.0% | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | 41.1% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -13.2% | 3.5% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | -1.3% | -33.3% | ||
| Q1 25 | -5.0% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | -9.0% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 0.7% | 2.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | 163.8% | -36.3% | ||
| Q1 25 | 3.7% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | 8.4% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.00 | $0.20 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | $0.52 | $-4.00 | ||
| Q1 25 | $0.01 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | $0.03 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $195.8M |
| Total DebtLower is stronger | $93.2M | — |
| Stockholders' EquityBook value | $1.2B | $1.2B |
| Total Assets | $1.8B | $1.4B |
| Debt / EquityLower = less leverage | 0.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $1.4B | $197.0M | ||
| Q3 25 | — | $167.8M | ||
| Q2 25 | $1.4B | $157.2M | ||
| Q1 25 | $836.1M | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | $802.5M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $93.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $93.4M | — | ||
| Q1 25 | $82.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $82.1M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $759.9M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | $740.1M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.8B | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $1.3B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | $5.8M |
| Free Cash FlowOCF − Capex | $3.4M | $1.1M |
| FCF MarginFCF / Revenue | 1.2% | 0.5% |
| Capex IntensityCapex / Revenue | 1.8% | 2.3% |
| Cash ConversionOCF / Net Profit | 4.21× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-96.2M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $8.2M | $46.9M | ||
| Q3 25 | — | $28.9M | ||
| Q2 25 | $-72.9M | $13.7M | ||
| Q1 25 | $40.3M | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | $-39.8M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $3.4M | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | $-82.2M | $5.6M | ||
| Q1 25 | $32.5M | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | $-49.9M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.2% | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | -29.6% | 2.8% | ||
| Q1 25 | 10.0% | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | -16.3% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.8% | 2.3% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | 3.3% | 4.0% | ||
| Q1 25 | 2.4% | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | 3.3% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 4.21× | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | 3.38× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | -1.54× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
